The founders of Inozyme Pharma observed the integral role of pyrophosphate, or PPi, in rare, debilitating, and life-threatening calcification disorders. These diseases can lead to over-calcification of soft tissues and under-mineralization of bone, with devastating consequences for patients.
In 2016, Inozyme Pharma acquired technology developed in the laboratory of Demetrios Braddock and licensed from Yale University. The name Inozyme Pharma reflects the company’s goal of developing an enzyme replacement therapy using inorganic PPi to treat calcification disorders = Inozyme.
Based on a deep understanding of the biology of calcification, the company is developing new medicines with the potential to drastically improve the standard of care and change treatment paradigms.